Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease. - Burton J; Brothers HM; Hutchison RM; Murphy J; Sun T; Dent G; Curiale G; Kowalski K (The journal of prevention of Alzheimer's disease, 2025)